11C- MET and 18F-Alfatide II dual-tracer PET/MR molecular imaging in differential diagnosis of radiation-induced brain injury and glioma recurrence

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100047602

Enrollment

Unknown

Registered

2021-06-20

Start date

2021-06-17

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioblastoma

Interventions

Gold Standard:pathological diagnosis

Index test:PET/MR

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Postoperative histopathological or biopsy diagnosis of glioblastoma and radiation therapy; 2. Routine MR follow-up showed that each patient had at least one new or progressive lesion suspected to be one of glioblastoma recurrence and radiation injury; 3. A definite diagnosis of radiation injury or glioblastoma recurrence.

Exclusion criteria

Exclusion criteria: 1. Contraindications for PET/MR, including pregnancy, metal implants, claustrophobia, allergies, or impaired renal function; 2. Serious image artifacts that affect imaging analysis; 3. The final diagnosis is incomplete.

Design outcomes

Primary

Measure	Time frame
Multimodal Molecular Imaging;SEN, SPE, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactDang Haodan

PLA General Hospital

shengdai23@126.com+86 13811960923

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026